在evolocumab和alirocumab试验中对基线失衡的定量评估:一项超流行病学研究

F H van Bruggen1, S U Zuidema1, H J Luijendijk2

  • 1Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Centre Groningen (UMCG), PO Box 196, Groningen, AD, 9700, The Netherlands.

概括

随机试验的PCSK9抑制剂如evolocumab和alirocumab经常有基线失衡. 患者特征中的这些差异可能会影响研究结果,并引起对随机化程序的担忧.